Tanshinone IIA attenuates atherosclerosis via inhibiting NLRP3 inflammasome activation. 2020

Jiexia Wen, and Yumei Chang, and Shanshan Huo, and Wenyan Li, and Heling Huang, and Yunhuan Gao, and Hongyu Lin, and Jianlou Zhang, and Yonghong Zhang, and Yuzhu Zuo, and Xuebin Cao, and Fei Zhong
College of Veterinary Medicine and College of Animal Science and Technology, Hebei Veterinary Biotechnology Innovation Center, Hebei Agricultural University, Baoding 071001, Hebei, China.

Tanshinone IIA (Tan IIA) possesses potent anti-atherogenic function, however, the underlying pharmacological mechanism remains incompletely understood. Previous studies suggest that oxidized LDL (oxLDL)-induced NLRP3 (NOD-like receptor (NLR) family, pyrin domain-containing protein 3) inflammasome activation in macrophages plays a vital role in atherogenesis. Whether the anti-atherogenic effect of Tan IIA relies on the inhibition of the NLRP3 inflammasome has not been investigated before. In this study, we found that Tan IIA treatment of high-fat diet fed ApoE-/- mice significantly attenuated NLRP3 inflammasome activation in vivo. Consistently, Tan IIA also potently inhibited oxLDL-induced NLRP3 inflammasome activation in mouse macrophages. Mechanically, Tan IIA inhibited NF-κB activation to downregulate pro-interleukin (IL) -1β and NLRP3 expression, and decreased oxLDL-induced expression of lectin-like oxidized LDL receptor-1 (LOX-1) and cluster of differentiation 36 (CD36), thereby attenuating oxLDL cellular uptake and subsequent induction of mitochondrial and lysosomal damage - events that promote the NLRP3 inflammasome assembly. Through regulating both the inflammasome 'priming' and 'activation' steps, Tan IIA potently inhibited oxLDL-induced NLRP3 inflammasome activation, thereby ameliorating atherogenesis.

UI MeSH Term Description Entries
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D000071199 NLR Family, Pyrin Domain-Containing 3 Protein An NLR protein that contains an N-terminal PYRIN DOMAIN and ATP-binding site and 9 C-terminal LEUCINE-rich repeats; it is expressed primarily by MACROPHAGES. It is a core component of the INFLAMMASOME and directs its assembly in response to pathogen infection and damage-associated stimuli. Mutations in the NLRP3 gene are associated with FAMILIAL COLD AUTOINFLAMMATORY SYNDROME. Cold Autoinflammatory Syndrome 1 Protein,NACHT, LRR and PYD Domains-Containing Protein 3,NLRP3 Protein,NACHT, LRR and PYD Domains Containing Protein 3,NLR Family, Pyrin Domain Containing 3 Protein
D000074085 Mice, Knockout, ApoE Strains of mice that contain genetic disruptions (knockout) of APOLIPOPROTEINS E genes. They are used as models for ATHEROSCLEROSIS research. Apo E Knockout Mice,ApoE Knockout Mice,Knockout Mice, ApoE,Mice, ApoE Knockout
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents
D001011 Aorta The main trunk of the systemic arteries. Aortas
D016328 NF-kappa B Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. Immunoglobulin Enhancer-Binding Protein,NF-kappa B Complex,Nuclear Factor kappa B,Transcription Factor NF-kB,kappa B Enhancer Binding Protein,Ig-EBP-1,NF-kB,NF-kappaB,Nuclear Factor-Kappab,Complex, NF-kappa B,Enhancer-Binding Protein, Immunoglobulin,Factor NF-kB, Transcription,Factor-Kappab, Nuclear,Ig EBP 1,Immunoglobulin Enhancer Binding Protein,NF kB,NF kappa B Complex,NF kappaB,NF-kB, Transcription Factor,Nuclear Factor Kappab,Transcription Factor NF kB
D045784 Abietanes A subclass of cyclical DITERPENES that contain the abietane ring structure. Abietane Diterpene,Abietane Diterpenoid,Abietane Diterpenoids,Diterpenes, Abietane,Isopimarane,Isopimaranes,Totarane Diterpene,Totarane Diterpenes,Totaranes,Diterpenes, Pimarane,Pimaranes,Abietane Diterpenes,Diterpene, Abietane,Diterpene, Totarane,Diterpenoid, Abietane,Pimarane Diterpenes
D050197 Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA. Atherogenesis,Atherogeneses,Atheroscleroses

Related Publications

Jiexia Wen, and Yumei Chang, and Shanshan Huo, and Wenyan Li, and Heling Huang, and Yunhuan Gao, and Hongyu Lin, and Jianlou Zhang, and Yonghong Zhang, and Yuzhu Zuo, and Xuebin Cao, and Fei Zhong
January 2015, Pharmacology, biochemistry, and behavior,
Jiexia Wen, and Yumei Chang, and Shanshan Huo, and Wenyan Li, and Heling Huang, and Yunhuan Gao, and Hongyu Lin, and Jianlou Zhang, and Yonghong Zhang, and Yuzhu Zuo, and Xuebin Cao, and Fei Zhong
October 2020, Endocrine,
Jiexia Wen, and Yumei Chang, and Shanshan Huo, and Wenyan Li, and Heling Huang, and Yunhuan Gao, and Hongyu Lin, and Jianlou Zhang, and Yonghong Zhang, and Yuzhu Zuo, and Xuebin Cao, and Fei Zhong
April 2019, International immunopharmacology,
Jiexia Wen, and Yumei Chang, and Shanshan Huo, and Wenyan Li, and Heling Huang, and Yunhuan Gao, and Hongyu Lin, and Jianlou Zhang, and Yonghong Zhang, and Yuzhu Zuo, and Xuebin Cao, and Fei Zhong
March 2024, Archives of biochemistry and biophysics,
Jiexia Wen, and Yumei Chang, and Shanshan Huo, and Wenyan Li, and Heling Huang, and Yunhuan Gao, and Hongyu Lin, and Jianlou Zhang, and Yonghong Zhang, and Yuzhu Zuo, and Xuebin Cao, and Fei Zhong
August 2018, Immunologic research,
Jiexia Wen, and Yumei Chang, and Shanshan Huo, and Wenyan Li, and Heling Huang, and Yunhuan Gao, and Hongyu Lin, and Jianlou Zhang, and Yonghong Zhang, and Yuzhu Zuo, and Xuebin Cao, and Fei Zhong
December 2020, Journal of cellular physiology,
Jiexia Wen, and Yumei Chang, and Shanshan Huo, and Wenyan Li, and Heling Huang, and Yunhuan Gao, and Hongyu Lin, and Jianlou Zhang, and Yonghong Zhang, and Yuzhu Zuo, and Xuebin Cao, and Fei Zhong
January 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Jiexia Wen, and Yumei Chang, and Shanshan Huo, and Wenyan Li, and Heling Huang, and Yunhuan Gao, and Hongyu Lin, and Jianlou Zhang, and Yonghong Zhang, and Yuzhu Zuo, and Xuebin Cao, and Fei Zhong
January 2015, International journal of clinical and experimental medicine,
Jiexia Wen, and Yumei Chang, and Shanshan Huo, and Wenyan Li, and Heling Huang, and Yunhuan Gao, and Hongyu Lin, and Jianlou Zhang, and Yonghong Zhang, and Yuzhu Zuo, and Xuebin Cao, and Fei Zhong
January 2017, Journal of cellular and molecular medicine,
Jiexia Wen, and Yumei Chang, and Shanshan Huo, and Wenyan Li, and Heling Huang, and Yunhuan Gao, and Hongyu Lin, and Jianlou Zhang, and Yonghong Zhang, and Yuzhu Zuo, and Xuebin Cao, and Fei Zhong
September 2013, International immunopharmacology,
Copied contents to your clipboard!